Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEnterprise ValueMarket CapitalizationPrice
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity RatioInvested Capital

Alterity Therapeutics (ATHE) Enterprise Value (2016 - 2025)

Alterity Therapeutics has reported Enterprise Value over the past 5 years, most recently at -$10.1 million for Q2 2019.

  • For Q2 2019, Enterprise Value rose 12.55% year-over-year to -$10.1 million; the TTM value through Jun 2019 reached -$10.1 million, up 12.55%, while the annual FY2019 figure was -$10.1 million, 12.55% up from the prior year.
  • Enterprise Value for Q2 2019 was -$10.1 million at Alterity Therapeutics, down from -$6.0 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$6.0 million in Q4 2018 and troughed at -$27.1 million in Q2 2015.
  • A 5-year average of -$16.7 million and a median of -$16.6 million in 2017 define the central range for Enterprise Value.
  • Biggest five-year swings in Enterprise Value: decreased 1.66% in 2016 and later surged 61.03% in 2018.
  • Year by year, Enterprise Value stood at -$20.9 million in 2015, then dropped by 1.66% to -$21.3 million in 2016, then grew by 27.41% to -$15.4 million in 2017, then surged by 61.03% to -$6.0 million in 2018, then tumbled by 67.72% to -$10.1 million in 2019.
  • Business Quant data shows Enterprise Value for ATHE at -$10.1 million in Q2 2019, -$6.0 million in Q4 2018, and -$11.5 million in Q2 2018.